Clinical Trials Sponsored by Zone Laboratories, Inc.

Total 370 results

Myriad Genetic Laboratories, Inc.

Recruiting

Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing

Prostate Cancer

United States
Heart Test Laboratories, Inc.

Active, not recruiting

MyoVista wavECG Clinical Validation Study Versus Low e' on Echocardiogram

Cardiac Disease

United States
Myriad Genetic Laboratories, Inc.

Terminated

Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6 (PROFUSE)

Colorectal Cancer, Metastatic

United States
Myriad Genetic Laboratories, Inc.

Completed

Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing (URO-009Low)

Prostate Cancer

United States
Myriad Genetic Laboratories, Inc.

Terminated

Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006) (ONC006)

NSCLC | Lung Cancer | NSCLC Adenocarcinoma

United States
Myriad Genetic Laboratories, Inc.

Withdrawn

Endometriosis Biomarker Discovery Study (EMBARK)

Endometriosis | Chronic Pelvic Pain
Myriad Genetic Laboratories, Inc.

Completed

Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients (PROCEDE-2000)

Prostate Cancer

United States
Unigene Laboratories Inc.
GlaxoSmithKline

Completed

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women

Postmenopausal Osteoporosis

Denmark, Estonia
Heart Test Laboratories, Inc.

Active, not recruiting

MyoVista wavECG Clinical Evaluation: >=60 y/o Enrichment Population

Health Screening

United States
Myriad Genetic Laboratories, Inc.

Terminated

Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer

Prostate Cancer

United States
Myriad Genetic Laboratories, Inc.

Terminated

EndoPredict® Extended Endocrine Trial (EXET)

Primary Invasive Breast Cancer

United States
G & W Laboratories Inc.

Completed

Safety and Efficacy Study of Anucort HC TM 25mg Rectal Suppositories to Treat Symptomatic Internal Hemorrhoids

Internal Hemorrhoids

United States
G & W Laboratories Inc.

Completed

Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
G & W Laboratories Inc.

Completed

Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Clinigen, Inc.
Prometheus Laboratories

Terminated

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma (PROCLIVITY01)

Metastatic Melanoma

United States
Myriad Genetic Laboratories, Inc.

Completed

Combined Breast Cancer Risk Study

Hereditary Cancer

United States
Myriad Genetic Laboratories, Inc.

Terminated

Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up (ONC003)

NSCLC | Lung Cancer | Lung Adenocarcinoma

United States
Myriad Genetic Laboratories, Inc.

Completed

Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients

Prostate Cancer

United States
Day One Biopharmaceuticals, Inc.

Available

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Low-grade Glioma
Day One Biopharmaceuticals, Inc.

Recruiting

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Melanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditions

United States, Canada, Korea, Republic of, Spain, Australia, Belgium, France
Ranbaxy Laboratories Limited
IPCA Laboratories Ltd.

Completed

Bioequivalence Study of Hydrochlorothiazide 50mg Tablets Under Fasting Conditions

Healthy
CAGE Bio Inc.
AMA Laboratories Inc.

Completed

50 Human Subject Repeat Insult Patch Test (HRIPT)

Erythema | Sensitisation

United States
Par Pharmaceutical, Inc.
PharmaKinetics Laboratories Inc.

Completed

A Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food Study

To Determine Bioequivalence Under Fed Conditions

United States
Applied Biological Laboratories Inc
Econometrica, Inc.

Completed

Alleviation of Common Cold Symptoms

Cough | Fever | Headache | Common Cold | Rhinorrhea | Sneezing | Pharyngitis | Congestion | Sore-throat | Sore Throats Viral | Malaise | Runny Nose

United States
Par Pharmaceutical, Inc.
PharmaKinetics Laboratories Inc.

Completed

Comparative Bioavailability Study of Lisinopril Tablets, 10 mg

Healthy

United States
CAGE Bio Inc.
BioScience Laboratories, Inc.

Completed

Clinical Evaluation of the Residual Antimicrobial Activity

Bacterial Overgrowth

United States
Laboratoire Boreaderme Inc.

Unknown

Study of a New Topical Natural Health Product for the Treatment of Herpes Labialis

Herpes Labialis

Canada
Starkey Laboratories, Inc
Clinimark, LLC

Withdrawn

Validation of In-Ear Sensor

Biometrics Measurement

United States
BeiGene
Myriad Genetic Laboratories, Inc.

Completed

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Solid Tumors

United States, Spain, United Kingdom, France, Australia, New Zealand
Tris Pharma, Inc.
Forest Laboratories

Completed

Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.

Low Back Pain

Austria, Belgium, Denmark, Finland, Germany, Hungary, Netherlands, Poland, Spain, Sweden, United Kingdom
Tris Pharma, Inc.
Forest Laboratories

Completed

Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects

Prolonged QTc Interval | Pharmacokinetic

United States
Tris Pharma, Inc.
Forest Laboratories

Completed

Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy

Pain | Diabetic Neuropathies

Bulgaria, Germany, Romania
Tris Pharma, Inc.
Forest Laboratories

Completed

Assessment of GRT6005 in Painful Osteoarthritis of the Knee

Osteoarthritis of the Knee

Austria, Poland, Spain
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Terminated

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (LIN-MD-63)

Irritable Bowel Syndrome With Constipation

United States, Canada
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

Functional Constipation in Children Ages 6-17 Years

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation | Chronic Constipation

United States, Canada
KGK Science Inc.
Neogenis Laboratories

Terminated

A Study to Investigate the Effect of a Nitric Oxide Supplementation on Pre- and Mildly Hypertensive Adults (15NBHN)

Pre-hypertension

Canada
Beachbody
Glycemic Index Laboratories, Inc

Completed

The Effect of a High Protein, High Fibre Shake Pre-load on Measures of Satiety and Subsequent Energy Intake

Overweight and Obesity

Canada
Joseph Hazelton

Completed

A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)

Pain | Nausea | Vomiting

United States
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study of Minocycline HCl 135 mg ER Tablet Sunder Fasting Conditions

Healthy
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study of Felodipine ER Tablets 10 mg Under Fed Conditions

Healthy
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study of Valsartan 320mg Tablets Under Fasting Conditions

Healthy

India
Forest Laboratories
Cypress Bioscience, Inc.

Terminated

Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia (MyFi)

Primary Fibromyalgia

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

Chronic Constipation

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome Characterized by Constipation

United States, Canada
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fed Conditions

Healthy

United States
Ranbaxy Laboratories Limited

Completed

A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fed Conditions

Healthy

United States
Ranbaxy Laboratories Limited

Completed

A Relative Bioavailability Study of Acetaminophen Extended Release Gel Tabs 650 mg Under Fasting Condition

Healthy

India
Forest Laboratories
Cypress Bioscience, Inc.

Completed

Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia

Fibromyalgia

United States

Clinical Trials Sponsored by Zone Laboratories, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations